Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Spectranetics executives indicted

This article was originally published in The Gray Sheet

Executive Summary

Three former executives and one contractor with Spectranetics face possible jail time and fines based on a twelve-count indictment on allegations that the company illegally imported unapproved devices into the U.S., the Colorado U.S. Attorney's Office and FDA's Office of Criminal Investigations announced Aug. 30. George John Schulte, former CEO of the excimer laser system maker, Obinna Adhigije, former VP of business development, Trung Pham, former business development manager, and Hernan Ricaurte, the contractor, are charged with conspiring to import devices based on false declarations, to introduce devices in the U.S. market without FDA approval or clearance, and to promote the devices for unauthorized uses, among other detailed counts. Spectranetics itself settled with the Department of Justice for $5 million on similar charges last December (1"The Gray Sheet" Jan. 4, 2010)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel